Lundbeck builds PD franchise with Prexton acquisition

H. Lundbeck A/S is to pay €100 million upfront to buy a six-year-old biotech that is developing a small molecule drug for treating the motor symptoms of Parkinson’s disease (PD). This will broaden its neurological franchise which includes PD.